Цель исследования: оценка клинических характеристик внекишечных (дерматологических) симптомов целиакии и синдрома мальабсорбции.Материалы и методы: в основу работы положены результаты определения антител к деамидированным пептидам глиадина (АГА IgА, IgG) и тканевой трансглутаминазе (tTG IgA, IgG) в цельной крови методом иммуноферментного анализа (ИФА). За трехлетний период были обследованы 1367 пациентов с распространенными хронически протекающими дерматозами.Результаты: положительные реакции на антитела к деамидированным пептидам глиадина и/или тканевой трансглутаминазе были обнаружены у 229 пациентов (117 мужчин и 112 женщин в возрасте от 18 до 70 лет), что составило 16,8% от общего числа обследованных. Из 229 серопозитивных пациентов 47 страдали псориазом, 27 -аллергическим дерматитом, 24 -красным плоским лишаем, 21 -атопическим дерматитом, 19 -экземой, 14 -акне, 13 -очаговым нейродермитом, 11 -герпетиформным дерматитом Дюринга, 11 -себорейным дерматитом,

The characteristics of the starting material and its active principles are given, which made it possible to scientifically substantiate the qualitative and quantitative composition of the prescription formula of a new specialized product. It is presented in the following biologically active additive form with directed functional properties, mg per one 0.6 g capsule: hydroxyl-cinnamic acids (kaftaric, chlorogenic, chicory), not less than 1.5; vitamin C – 60; rutine – 30; glycyrrhizic acid, not less than 2; zinc – 2.5; selenium – 0.0065. The hygienic quality of the developed product is shown, following regulated indicators of nutritional value defining its functional orientation are determined, mg/1 capsule: rutin – 30 (24-36); ascorbic acid – 60 (48-72); zinc – 2.5 (2.0 – 3.0); hydroxycinnamic acids, not less than 1.5; glycyrrhizic acid – 2.0. The regulated production parameters, which ensure the preservation of biologically active components of the formulation, are determined. The use of gelatin capsules allows combining prescription ingredients, protecting the contents from the effects of adverse factors, providing the necessary delivery speed to the target cell and localizing the action. Clinical trials of the effectiveness and functional properties of the developed product have been carried out by including it in the diet of children with acute respiratory diseases, such as bronchitis and pneumonia. The prescription of diet therapy provided an earlier return to normal life, cough and wheezing, swelling and hyperemia of the nasopharynx stopped faster. Research materials indicate the activation of immunity, increasing the body’s resistance to infection. The results obtained indicate the advisability of including the phytocomplex in the complex therapy of considered patients, and also using it as a prophylactic for weakened children.

The surface of the intestinal tract in healthy people is free of bacteria in all segments of the intestine. Thus, the attachment of bacteria to epithelial cells is a sign of infection. Unlike the mucous membrane, the intestinal lumen is never sterile. The reason for this is the polymicrobial nature of the gut microbiota. In the intestine, segments such as the stomach or small intestine, where bacteria are actively suppressed, the microbiota is random in appearance, composition, and concentration. However, the situation is completely different in the colon, where the growth of bacteria increases and their suppression is suspended. The concentration and diversity of bacteria in the colon reaches astronomical numbers. Some of these bacteria are required for the colon to function. Many of the local bacteria in the colon are potential pathogens: Bacteroides, Enterobacteriaceae, Enterococci, and Clostridium histolyticum. Control of pathogens in the colon is achieved through an impenetrable mucus layer. Inflammatory bowel disease is a polymicrobial infection characterized by persistent disruption of the mucosal barrier, subsequent migration of bacteria to the mucous membrane, and overgrowth of a complex bacterial biofilm on the surface of the epithelium, resulting in invasive and cytopathological effects. As long as the mucosal barrier function is impaired, the inflammatory process cannot successfully remove bacteria from the mucosal surface, and inflammation itself is detrimental. Due to the inflammatory reaction, the composition and structure of the fecal microbiota changes. Based on the biostructure of the fecal casts, active Crohn’s disease and ulcerative colitis can be distinguished from each other and from other gastrointestinal diseases. The relationship between the gut microbiome and various dermatological diseases (psoriasis, acne, rosacea, atopic dermatitis) is discussed.